Baseline patient characteristics
| Characteristic . | Total N= 25 n (%) . | |
|---|---|---|
| Median age, y (range): 55 (30-78) | ||
| Sex | Male | 13 (52) |
| ECOG | 0 | 21 (84) |
| 1 | 3 (12) | |
| 2 | 1 (4) | |
| Ann Arbor Stage | II | 2 (8) |
| III/IV | 23 (92) | |
| FL grade | 1 or 2 | 19 (76) |
| 3a | 6 (24) | |
| FLIPI | Low risk (0-1) | 5 (20) |
| Intermediate risk (2) | 8 (32) | |
| High risk (3-5) | 12 (48) | |
| Reason for treatment start (>1 possible) | B-symptoms | 10 (40) |
| Bulky disease (≥6 cm) | 11 (44) | |
| Progression in the last 6 mo | 13 (52) | |
| Symptomatic disease | 20 (80) | |
| Characteristic . | Total N= 25 n (%) . | |
|---|---|---|
| Median age, y (range): 55 (30-78) | ||
| Sex | Male | 13 (52) |
| ECOG | 0 | 21 (84) |
| 1 | 3 (12) | |
| 2 | 1 (4) | |
| Ann Arbor Stage | II | 2 (8) |
| III/IV | 23 (92) | |
| FL grade | 1 or 2 | 19 (76) |
| 3a | 6 (24) | |
| FLIPI | Low risk (0-1) | 5 (20) |
| Intermediate risk (2) | 8 (32) | |
| High risk (3-5) | 12 (48) | |
| Reason for treatment start (>1 possible) | B-symptoms | 10 (40) |
| Bulky disease (≥6 cm) | 11 (44) | |
| Progression in the last 6 mo | 13 (52) | |
| Symptomatic disease | 20 (80) | |